AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2018-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1124/jpet.117.246132PMID 29549158
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial

  2018cited by this paper
• Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

  2017cited by this paper
• Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects

  2015influential reference
• Lipopolysaccharide challenge: immunological effects and safety in humans

  2015cited by this paper
• Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease

  2015cited by this paper
• Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial

  2013cited by this paper
• COPD Surveillance—United States, 1999-2011

  2013cited by this paper
• Epidemiology of chronic obstructive pulmonary disease: a literature review

  2012cited by this paper
• Inhalation of LPS induces inflammatory airway responses mimicking characteristics of chronic obstructive pulmonary disease

  2012cited by this paper
• Optimisation of DMPK by the inhaled route: challenges and approaches.

  2012cited by this paper
• Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs

  2012cited by this paper
• p38 mitogen-activated protein kinase pathways in asthma and COPD.

  2011cited by this paper
• Anti-Inflammatory Properties of a Novel N-Phenyl Pyridinone Inhibitor of p38 Mitogen-Activated Protein Kinase: Preclinical-to-Clinical Translation

  2009influential reference
• SD0006: A Potent, Selective and Orally Available Inhibitor of p38 Kinase

  2009cited by this paper
• Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.

  2009cited by this paper
• Increased activation of p38 MAPK in COPD

  2008cited by this paper
• LPS inhalation challenge: a new tool to characterize the inflammatory response in humans

  2007cited by this paper
• Endotoxin: the uninvited guest.

  2005cited by this paper
• The p38 MAP kinase pathway as a therapeutic target in inflammatory disease.

  2004cited by this paper
• Local versus systemic effects of inhaled drugs

  2004cited by this paper
• Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.

  2000cited by this paper
• Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects

  1998cited by this paper
• Dose-response relationship to inhaled endotoxin in normal subjects.

  1997cited by this paper
• Local versus systemic effects of inhaled drugs.

  1997cited by this paper
• Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements.

  1996cited by this paper
• A study of the mechanism of the antiasthmatic action of inhaled budesonide.

  1990cited by this paper

• POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study

  2026cites this paper
• CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder

  2024cites this paper
• Developing inhaled drugs for respiratory diseases: a medicinal chemistry perspective.

  2021cites this paper
• The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors.

  2020cites this paper
• Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19

  2020cites this paper